Obstetrics & Gynecology · Medical Literature
Effects of vitamin D supplementation on insulin resistance and lipid metabolic profiles in women with gestational diabetes mellitus: A randomized controlled trial.
Abstract
Gestational diabetes mellitus (GDM) commonly presents as insulin resistance and altered lipid metabolism, with evidence linking vitamin D deficiency to its pathogenesis. In this randomized, double-blind, placebo-controlled trial, 120 pregnant women diagnosed with GDM were assigned to receive either vitamin D3 supplements (2000 IU/day) or a placebo for 3 months. Serum vitamin D status, glycemic control parameters, and lipid profiles were evaluated pre- and post-intervention, adjusting for dietary and exercise confounders. After the 3-month intervention, serum 25-hydroxyvitamin D levels in the vitamin D group were significantly higher than those in the placebo group. Vitamin D supplementation effectively reduced fasting plasma glucose, fasting insulin, and HOMA-IR scores. Simultaneously, it significantly decreased triglycerides and LDL-C levels while increasing HDL-C. Total cholesterol levels showed no statistically significant difference between the two groups. Supplementation with 2000 IU vitamin D per day for 3 months yields significant improvements in glucose homeostasis and lipid metabolism in the GDM population. Vitamin D holds promise as an effective auxiliary treatment to enhance maternal metabolic health.
Clinical relevance
Does daily supplementation with 2000 IU of vitamin D3 for 3 months improve insulin resistance and lipid metabolic profiles in pregnant women with gestational diabetes mellitus compared with placebo? __SNAPSHOT__ {"studyDesign":"Randomized, double-blind, placebo-controlled trial","setting":"Department of Nutrition, Beijing Chaoyang Hospital of Capital Medical University, Beijing, China (single-center)","sampleSize":"n=120 (intervention: 60, control: 60; inferred from equal allocation — not explicitly confirmed in abstract)","population":"Pregnant women diagnosed with gestational diabetes mellitus (GDM); specific gestational age range, baseline vitamin D status, diagnostic criteria for GDM, and comorbidity exclusion criteria not reported in the abstract","intervention":"Vitamin D3 2000 IU orally once daily for 3 months, with adjustment for dietary and exercise confounders","comparator":"Matched placebo for 3 months","primaryOutcome":"Not formally designated as a single primary endpoint in the abstract; evaluated outcomes include serum 25-hydroxyvitamin D, fasting plasma glucose, fasting insulin, HOMA-IR, triglycerides, LDL-C, HDL-C, and total cholesterol","followUp":"3 months (pre- and post-intervention assessment)","fundingSource":"Not reported"}
Key findings
After 3 months of intervention, the vitamin D group demonstrated significantly higher serum 25-hydroxyvitamin D levels compared to placebo (magnitude of between-group difference not reported in the abstract). Vitamin D supplementation was associated with statistically significant reductions in fasting plasma glucose, fasting insulin, and HOMA-IR versus placebo; however, absolute effect sizes, confidence intervals, and p-values for these glycemic outcomes are not reported in the available abstract. Similarly, triglycerides and LDL-C were significantly decreased, and HDL-C was significantly increased in the vitamin D group, with no specific magnitude of effect or confidence intervals provided. Total cholesterol did not differ significantly between groups. No adverse events or safety data are described. NNT/NNH cannot be calculated from the available data. All inferential statistics beyond directional claims of significance are not reported.
Practice implications
This double-blind RCT provides directional evidence suggesting that 2000 IU/day of vitamin D3 for 3 months may improve markers of insulin resistance and a subset of lipid parameters in women with GDM. These findings are biologically plausible given proposed mechanisms by which vitamin D modulates pancreatic beta-cell function, insulin receptor sensitivity, and hepatic lipid metabolism. However, the clinical importance of these findings cannot be fully evaluated without reported absolute values, effect sizes, and confidence intervals. Notably, the existing literature is heterogeneous: some prior RCTs in GDM have found glycemic benefit without significant lipid improvement, while others found neither. The current study's simultaneous demonstration of benefit across both glycemic and lipid domains is a notable finding but requires independent replication. Results apply to women with GDM receiving standard obstetric care in a single Chinese tertiary nutrition department and may not generalize to populations with different ethnic backgrounds, baseline vitamin D status, GDM severity, or concomitant treatments. Key patient subgroups — including those with severe vitamin D deficiency at baseline, obesity, or twin pregnancies — were not separately analyzed. Maternal and neonatal clinical outcomes (e.g., preeclampsia, cesarean delivery, macrosomia, neonatal hypoglycemia) were not reported. IMPORTANT LIMITATION: This summary is based solely on the published abstract; the full manuscript was not available for review, and critical methodological details (randomization method, allocation concealment, blinding fidelity, attrition, baseline characteristics, statistical analysis plan, and definition of GDM) cannot be verified. __LIMITATIONS__ Abstract-only review: essential methodological details including GDM diagnostic criteria, gestational age at enrollment, allocation concealment, attrition rates, and statistical analysis plan are not assessable.,No primary endpoint formally pre-specified: testing multiple metabolic outcomes (glycemic + lipid panel) without a designated primary endpoint inflates the risk of type I error.,No absolute effect sizes, confidence intervals, or p-values reported for any outcome; clinical significance cannot be independently evaluated.,Single-center study from a tertiary nutrition department in Beijing; generalizability to diverse populations, primary care settings, or different healthcare systems is limited.,Short follow-up of 3 months: does not capture third-trimester metabolic trajectory, delivery outcomes, or postpartum metabolic normalization.,No maternal or neonatal clinical endpoints reported; improvements in surrogate metabolic markers may not translate to reductions in adverse obstetric outcomes.,Baseline vitamin D status of participants not described; treatment effect may be heterogeneous depending on the degree of baseline deficiency.,Dietary and exercise confounders were adjusted for, but the method of adjustment is not specified in the abstract.,Funding source not reported; potential conflicts of interest cannot be assessed.,Total cholesterol was not significantly different between groups, which is partially discordant with the lipid improvement narrative and warrants mechanistic explanation. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small double-blind RCT found that vitamin D3 2000 IU/day for 3 months was associated with statistically significant improvements in fasting glucose, insulin resistance (HOMA-IR), triglycerides, LDL-C, and HDL-C in women with GDM, but provides no quantitative effect sizes or confidence intervals to permit independent clinical appraisal. Given a heterogeneous prior evidence base, single-center design, abstract-only availability, and absence of hard obstetric or neonatal endpoints, these findings are preliminary and hypothesis-generating rather than practice-changing. Clinicians managing GDM should await adequately powered, multi-center replication with pre-specified primary endpoints and clinical outcome data before integrating 2000 IU/day vitamin D supplementation as a standard adjunct solely on the basis of metabolic surrogates.